DEVICES
| Artificial pancreas |
| Continuous glucose monitoring systems |
| Alternative routes of peptide administration |
| mHealth applications |
BIOLOGICS
BIOLOGICS
| Insulins |
| Ultra-rapid, rapid-, long- and ultra-long acting NCEs, biosimilar insulins, inhaled and oral insulins |
| Incretins mimetics |
| Incretins (GLP-1, GIP, GCGR), mono, dual and triple agonists, oxyntomodulin analogs |
| Other glucoregulatory peptides & proteins |
| Amylin analogues, peptide YY (3-36), fibroblast growth factors (FGF21), insulin-like growth factor 1 |
| Immune-modulation & beta cell regeneration |
| Monoclonal antibodies, islet neogenesis associated protein (INGAP) |
OLIGONUCLEOTIDES
miRNA-based therapeutics
SMALL MOLECULES
SMALL MOLECULES
| Insulin secretagogues |
| Sulfonylureas, meglitinides, glucokinase activators, GPR40, GPR119, GPR44 agonists |
| Insulin sensitizers |
| Biguanides, PPAR agonists, SARMs, SIRT1 activators, 11beta-HSD1 inhibitors |
| Incretin/glucagon pathway modulators |
| Dipeptidyl peptidase-4 inhibitors, glucagon-receptor antagonists |
| SGLT-2 Inhibitors |
| Other oral agents |
| Diacylglycerol acyltransferase and ACC inhibitors, thyroid hormone receptor beta (TRĪ²) agonists, farnesoid X receptor (FXR) agonists, peroxisome proliferator-activated receptor, niacin derivatives, CCR2 antagonists, ileal bile acid transport (IBAT) inhibitors, PDF4 inhibitors, de novo lipogenesis (DGAT, SCD1 & ACC) inhibitors, cannabinoid 1 receptor modulator |
